[image] [image] Ressource protégée - Nantes Université Accéder directement au contenu

*[image] [image]*

• Documentation

• FR
Français (FR)

• Anglais (EN)
Se connecter

• Portail HAL Nantes Université

• Recherche
Loading...

## Recherche avancée

Information de documents

Titres

○ Titres

○ Sous-titre

○ Titre de l'ouvrage

○ Titre du volume (Série)

○ Champ de recherche par défaut (multicritères) + texte intégral des PDF

○ Résumé

○ Texte intégral indexé des documents PDF

○ Mots-clés

○ Type de document

○ Sous-type de document

○ Tous les identifiants du document

○ Identifiant HAL du dépôt

○ Langue du document (texte)

○ Pays (Texte)

○ Ville

○ À paraître (true ou false)

Ajouter

Auteur
# Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study

Pierre Ménager, Olivier Brière, Jennifer Gautier, Jérémie Riou, Guillaume Sacco, Antoine Brangier, Cédric Annweiler

► To cite this version:

Pierre Ménager, Olivier Brière, Jennifer Gautier, Jérémie Riou, Guillaume Sacco, et al. Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. Nutrients, 2020, 13 (1), pp.39. 10.3390/nu13010039. hal-04595894

HAL Id: hal-04595894

https://nantes-universite.hal.science/hal-04595894v1

Submitted on 31 May 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
## Auteur (multicritères)

○ Auteur (multicritères)

○ Auteur : Nom complet

○ Auteur : Nom de famille

○ Auteur : Prénom

○ Auteur : Complément de nom, deuxième prénom

○ Auteur : Organisme payeur

○ Auteur : IdHal (chaîne de caractères)

○ Auteur : Fonction

○ Auteur : personID (entier)

○ Auteur : Identifiant de l'organisme payeur

○ Auteur : Identifiant de la structure

○ Directeur de thèse

○ Éditeur

○ Éditeur scientifique

○ Éditeur de la série

## Ajouter

### Structure

### Structure (multicritères)

○ Structure (multicritères)

○ Structure : Acronyme

○ Structure : Nom

○ Structure : Code

○ Structure : Pays

○ Structure : Type

○ Structure : État dans le référentiel

○ Structure : Identifiant HAL de la structure

○ Structure/équipe de recherche : Pays

○ Structure/regroupement d'équipes : Pays

○ Structure/laboratoire : Pays

○ Structure/regroupement de laboratoires : Pays

○ Structure/institution : Pays

○ Structure/regroupement d'institutions : Pays

## Ajouter

## Autres
<figure><img src="image_2.png" /></figure>

Article

# Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study

Pierre Ménager<sup>1,2</sup>, Olivier Brière<sup>2</sup>, Jennifer Gautier<sup>2 ID</sup>, Jérémie Riou<sup>3,4</sup>, Guillaume Sacco<sup>2 ID</sup>, Antoine Brangier<sup>2</sup>, Cédric Annweiler<sup>1,2,5,6,7,* ID</sup> and on behalf of the GERIA-COVID study group<sup>†</sup>

**Abstract:** Background. Vitamin K concentrations are inversely associated with the clinical severity of COVID-19. The objective of this cohort study was to determine whether the regular use of vitamin K antagonist (VKA) prior to COVID-19 was associated with short-term mortality in frail older adults hospitalized for COVID-19. Methods. Eighty-two patients consecutively hospitalized for COVID-19 in a geriatric acute care unit were included. The association of the regular use of VKA prior to COVID-19 with survival after 7 days of COVID-19 was examined using a propensity-score-weighted Cox proportional-hazards model accounting for age, sex, severe undernutrition, diabetes mellitus, hypertension, prior myocardial infarction, congestive heart failure, prior stroke and/or transient ischemic attack, CHA2DS2-VASc score, HAS-BLED score, and eGFR. Results. Among 82 patients (mean ± SD age 88.8 ± 4.5 years; 48% women), 73 survived COVID-19 at day 7 while 9 died. There was no between-group difference at baseline, despite a trend for more frequent use of VKA in those who did not survive on day 7 (33.3% versus 8.2%, *p* = 0.056). While considering "using no VKA" as the reference (hazard ratio (HR) = 1), the HR for 7-day mortality in those regularly using VKA was 5.68 [95% CI: 1.17; 27.53]. Consistently, COVID-19 patients using VKA on a regular basis had shorter survival times than the others (*p* = 0.031). Conclusions. Regular use of VKA was associated with increased mortality at day 7 in hospitalized frail elderly patients with COVID-19.

**Keywords:** COVID-19; SARS-CoV-2; vitamin K antagonist; anticoagulation; survival; older adults

## 1. Introduction

The coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 has been spreading worldwide since December 2019, affecting millions of people of all ages. While the majority of patients exhibit only mild symptoms [1], older adults have a worse prognosis, either due to the onset of acute respiratory distress syndrome (ARDS) [2] or due to other manifestations, including coagulopathy and thromboembolic disease [2,3].

Interestingly, previous studies have suggested that vitamin K concentrations are decreased in patients with COVID-19 compared to uninfected controls and are inversely associated with the clinical severity of COVID-19 [4]. Such poor COVID-19 outcomes

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Ménager, P.; Brière, O.; Gautier, J.; Riou, J.; Sacco, G.; Brangier, A.; Annweiler, C.; Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study. *Nutrients* **2021**, *13*, 39. https://dx.doi.org/10.3390/nu13010039

Received: 26 November 2020

Accepted: 22 December 2020

Published: 24 December 2020

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1">¹ Department of Geriatric Medicine, Le Mans Hospital, F-72037 Le Mans, France; pierrebenoitmenager@yahoo.fr</footnote>

<footnote n="2">² Department of Geriatric Medicine and Memory Clinic, Research Center on Autonomy and Longevity, University Hospital, F-49933 Angers, France; olivierbriere53@gmail.com (O.B.); jegautier@chu-angers.fr (J.G.); yogisacco@gmail.com (G.S.); Antoine.Brangier@chu-angers.fr (A.B.)</footnote>

<footnote n="3">³ INSERM, MINT, 1066, University of Angers, F-49000 Angers, France; jeremie.riou@univ-angers.fr</footnote>

<footnote n="4">⁴ Delegation to Clinical Research and Innovation, Angers University Hospital, F-49933 Angers, France</footnote>

<footnote n="5">5 UPRES EA 4638, University of Angers, F-49000 Angers, France</footnote>

<footnote n="6">⁶ Gérontopôle Autonomie Longévité des Pays de la Loire, F-44000 Nantes, France</footnote>

<footnote n="7">7 Robarts Research Institute, Department of Medical Biophysics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, ON N6A 5K8, Canada</footnote>

<footnote>* Correspondence: Cedric.Annweiler@chu-angers.fr; Tel.: +33-2-4135-4725; Fax: +33-2-4135-4894</footnote>

<footnote>† Membership of the GERIA-COVID study group is provided in the Acknowledgments.</footnote>
Champ de recherche par défaut (multicritères)

○ <u>Champ de recherche par défaut (multicritères)</u>

○

○ <u>Revues (multicritères)</u>

○ <u>Revue : Éditeur</u>

○ <u>Revue : Titre abrégé</u>

○ <u>Revue : Titre</u>

○ <u>Revue : Identifiant interne</u>

○ <u>Revue : Date de début de publication</u>

○ <u>Revue : ISSN électronique</u>

○ <u>Revue : ISSN</u>

○ <u>Revue : Éditeur</u>

○ <u>Revue : Couleur dans SHERPA/RoMEO</u>

○ <u>Revue : État dans le référentiel</u>

○

○ <u>Colloque (multicritères)</u>

○ <u>Colloque : Titre</u>

○ <u>Colloque : Organisateur</u>

○ <u>Colloque : date de début (Année)</u>

○ <u>Colloque : date de fin (Année)</u>

○ <u>Conférence invitée (oui/non)</u>

○

○ <u>Projets ANR (multicritères)</u>

○ <u>Projet ANR : Acronyme</u>

○ <u>Projet ANR : Acronyme du programme</u>

○ <u>Projet ANR : Code décision (référence)</u>

○ <u>Projet ANR : Nom</u>

○ <u>Projet ANR : Identifiant interne</u>

○ <u>Projet ANR : État dans le référentiel</u>

○

○ <u>Projets européens (multicritères)</u>

○ <u>Projet européen : Acronyme</u>

○ <u>Projet européen : Identifiant de l'appel à projet</u>

○ <u>Projet européen : Référence</u>

○ <u>Projet européen : Nom</u>

○ <u>Projet européen : Date de fin</u>

○ <u>Projet européen : Financement</u>

○ <u>Projet européen : Date de début</u>

○ <u>Projet européen : État dans le référentiel</u>
accompanying low vitamin K concentrations may be explained by the deregulation of coagulation in the case of low vitamin K status, the increase in circulating levels of inflammatory cytokines, the onset of lung fibrosis, and by the promotion of comorbidities such as hypertension or diabetes mellitus that worsen the prognosis of COVID-19 [1,5,6].

In this perspective, it is noticeable that the regular use of vitamin K antagonists (VKAs) dramatically decreases the bioavailability of active vitamin K. VKAs are drugs commonly used for the prophylaxis and treatment of thromboembolic disease in older adults [7,8]. However, data on COVID-19 outcomes within the patients using VKA on a regular basis are still lacking. While VKAs are useful—but not the only drug option—to prevent thromboembolic complications in COVID-19 [9], we are concerned about the reduced vitamin K concentrations they cause and the possible life-threatening implications during COVID-19. We hypothesized that, by decreasing the bioavailability of active vitamin K, VKAs might be accompanied by reduced survival in older patients with COVID-19. The objective of the present cohort study was to determine whether the regular use of VKA prior to COVID-19 was associated with increased mortality compared to not using VKA among frail older adults hospitalized for COVID-19.

**2. Materials and Methods**

**2.1. Study Population**

The GERIA-COVID study consisted of a longitudinal observational study in one French geriatric acute care unit dedicated to COVID-19 patients during the first wave (ClinicalTrials.gov Identifier: NCT04560608). Data of the GERIA-COVID study were retrospectively collected from hospital records. The inclusion criteria in the study were as follows: (1) patients hospitalized in the geriatric acute care unit of the University Hospital of Angers, France, in March–June 2020; (2) no objection from the patient and/or relatives to the use of anonymized clinical and biological data for research purpose. The inclusion criteria for the present analysis were as follows: (1) diagnosis of COVID-19 with RT-PCR and/or chest CT-scan; (2) age 80 and over; (3) data available on the regular use of VKA and on the heart rhythm on hospital admission; (4) no introduction of VKA during the hospitalization for COVID-19; (5) data available on the vital status within 7 days after the diagnosis of COVID-19. Ninety-seven patients were consecutively diagnosed with COVID-19 during the study period in the geriatric acute care unit and were recruited in the GERIA-COVID study. Among them, 5 were aged less than 80 years, 1 had VKA started during the hospitalization, 9 had missing data on heart rhythm. Finally, 82 patients could be included in the present analysis.

**2.2. Regular Use of Vitamin K Antagonists**

The regular use of VKA (i.e., warfarin or acenocoumarol or fluindione) was noted from family physician prescriptions and sought by questioning the patients and relatives, regardless of the prescription period, the reason for anticoagulation and the history of the international normalized ratio (INR).

**2.3. Outcome: 7-Day Mortality in COVID-19 Patients**

The main outcome was the 7-day all-cause mortality. Follow-up started from the day of COVID-19 diagnosis for each patient and continued for 7 days or until death when applicable. This follow-up period was covered by the hospitalization for all patients.

**2.4. Covariables**

Covariables were age, sex, functional abilities, history of cancer, severe undernutrition, diabetes mellitus, hypertension, cardiomyopathy, myocardial infarction, non-sinus heart rhythm, congestive heart failure, stroke and/or transient ischemic attack, CHA2DS2-VASc score for atrial fibrillation stroke risk, HAS-BLED score for major bleeding risk, use of antibiotics and/or of pharmacological treatments of respiratory disorders, and estimated glomerular filtration rate (eGFR).
○ Projet européen : Identifiant interne

○

○ Date de production : année

○ Date de mise en ligne : année

○ Date de publication : année

○ Date d'écriture : année

○ Date de modification du dépôt : année

○ Date de dépôt : année

○ Date de publication électronique : année

○

○ Collection HAL (multicritères)

○ Collection HAL : catégorie

○ Collection HAL : Code

○ Collection HAL : Nom

○ Collection HAL : Identifiant interne

○

○ Identifiant interne du contributeur/déposant

○ Nom complet du contributeur/déposant

○

○ Domaines

○ Domaine primaire

○ Domaine racine

○ Sous-domaine niveau 1

○ Sous-domaine niveau 2

○ Sous-domaine niveau 3

○

○ Statut du document

○ Version du document

○ Type de dépôt

○ Type de document

○ ISBN

○ Numéro - référence

○ Identifiant DOI

○

○ Classification

○ Audience

○ Vulgarisation

○ Comité de lecture - texte (oui ou non)

○ Actes de colloque

○ Référence interne
Functional abilities prior to COVID-19 were measured from 1 to 6 (best) with the iso-
resources groups (GIR) [10]. History of hematological and solid cancers, diabetes mellitus,
of hypertension, of cardiomyopathy, of myocardial infarction, of congestive heart failure,
and of stroke and/or transient ischemic attack were noted from the medical register and
by interviewing patients, their relatives and family physicians. Severe undernutrition
was defined as serum albumin concentration < 30 g/L at the time of COVID-19 diagnosis.
The heart rhythm was analyzed from the electrocardiogram on hospital admission. All
non-sinus rhythms were identified, including atrial fibrillation. The risks of stroke and
of major bleeding in atrial fibrillation were estimated using the consensual CHA2DS2-
VASc and HAS-BLED scores, respectively [11]. The use of antibiotics (i.e., quinolones,
beta-lactams, sulfonamides, macrolides, lincosamides, aminoglycosides, among others)
and/or pharmacological treatments of respiratory disorders (i.e., beta2-adrenergic agonists,
inhaled corticosteroids, antihistamines, among others) were noted from prescriptions
during hospitalization. eGFR was estimated with the modification of diet in renal disease
(MDRD) study equation using the measure of serum creatinine concentration collected at
the time of the diagnosis of COVID-19.

## 2.5. Statistical Analysis

The participants' characteristics were summarized using medians and interquar-
tile ranges (IQR) or numbers and percentages, as appropriate. Comparisons between
participants separated according to the vital status at day 7 of the diagnosis of COVID-
19 were performed using the nonparametric Mann-Whitney test or Fisher's exact test,
as appropriate.

Weighting-based propensity scores (inverse probability weighting) were used to balance covariables between the participants regularly using VKA and the others. All major variables were taken into account: age, sex, severe undernutrition, diabetes mellitus, hypertension, prior myocardial infarction, congestive heart failure, prior stroke and/or transient ischemic attack, CHA2DS2-VASc score, HAS-BLED score, and eGFR. The balance between groups was performed using the average treatment effect (ATE) [12]. Once the profiles of participants were balanced between the two groups, a propensity-score-weighted Cox proportional-hazards model was performed to determine the survival during the 7-day follow-up according to the use of VKA prior to COVID-19.

A sensitivity analysis was also conducted in order to confirm the results obtained with the propensity score, using a more classical approach based on multiple Cox models. Unadjusted, partially adjusted (accounting for age, sex, functional ability and non-sinus heart rhythm) and fully adjusted (accounting for age, sex, functional abilities, history of cancer, hypertension, cardiomyopathy, non-sinus heart rhythm, use of antibiotics and/or of pharmacological treatments of respiratory disorders, and eGFR) Cox regressions were used to examine the associations of the regular use of VKA (independent variable) with the 7-day mortality (dependent variable). Scaled Schoenfeld residuals were computed to check the proportionality assumption. A statistical test was performed to validate the non-proportionality combined with a plot of these residuals against time. Hazard ratios (HR) with 95% confidence intervals (95% CI) were reported.

Finally, the relapsed time to death was illustrated by survival curves computed
without propensity score adjustment, according to Kaplan-Meier estimator.

p-Values < 0.05 were considered significant. All statistics were performed using SAS®
version 9.4 software (SAS Institute Inc.) and R (R core team, 2018).

## 2.6. Ethics

The study was conducted in accordance with the ethical standards set forth in the
Helsinki Declaration (1983). All participants and relatives were informed in writing and
orally of the data collection, and none objected to the use of anonymized clinical and
biological data for research purposes, as approved by the Ethics Board of the University
○ Financement

○ Collaborations

Ajouter

Lancer la recherche

Recherche experte (SolR)

Recherche experte (SolR)

Lancer la recherche

Vers la recherche avancée

• [Déposer](#)

[image](#)

• [Accueil](#)

• [Consulter](#)

○ [Consultation par période](#)

○ [Consultation par auteur](#)

○ [Consultation par collection de laboratoires](#)

○ [Consultation par discipline](#)

○ [Consultation des dernières publications](#)

○ [Consultation par type de publication](#)

○ [Consultation par éditeur](#)

○ Vérifiez si vos publications sont sur HAL

○ Calculez votre score Open Access !

• [Collaborations internationales](#)

• [Autres archives ouvertes](#)

○ arXiv

○ Pub Med Central

○ RePEc

X

X

X

Loading...
Hospital of Angers, France (2020/100). The study protocol was also declared to the National Commission for Information Technology and Civil Liberties (CNIL; ar20-0087v0).

### 3. Results

Eighty-two participants (mean ± SD age 88.8 ± 4.5 years; 48% women; 11% using VKA prior to COVID-19; none using direct oral anticoagulant (DOAC); 24.4% using an antiplatelet agent; none using both VKA and antiplatelet agent) were included in the present analysis. A switch to heparin anticoagulant therapy (either low molecular weight heparin or unfractionated heparin depending on renal function) was made for all participants using VKA upon diagnosis of COVID-19, as recommended [13]. Finally, 73 participants survived COVID-19 on day 7, while 9 died.

Table 1 indicates the characteristics of participants separated according to survival at day 7. There was no between-group difference, despite a trend for more frequent use of VKA prior to COVID-19 in those who did not survive on day 7 (33.3% versus 8.2%, *p* = 0.056).

<table><caption>**Table 1.** Characteristics and comparison of COVID-19 participants (n = 82) separated into two groups according to 7-day mortality.</caption><thead><tr><th rowspan="2"></th><th rowspan="2">Total Cohort<br>(n = 82)</th><th colspan="2">7-Day Mortality</th><th rowspan="2">p-Value *</th></tr><tr><th>No<br>(n = 73)</th><th>Yes<br>(n = 9)</th></tr></thead><tbody><tr><td><strong>Demographical data</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years), med (IQR)</td><td>88 (85–92)</td><td>88 (85–92)</td><td>89 (87–92)</td><td>0.655</td></tr><tr><td>Female sex</td><td>39 (47.6)</td><td>35 (48.0)</td><td>4 (44.4)</td><td>1.000</td></tr><tr><td>GIR score (/6), med (IQR)</td><td>4 (2–4)</td><td>4 (2–4)</td><td>3 (2–4)</td><td>0.387</td></tr><tr><td><strong>History and treatment data</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>History of cancer</td><td>29 (35.4)</td><td>23 (31.5)</td><td>6 (66.7)</td><td>0.061</td></tr><tr><td>Severe undernutrition †</td><td>25 (30.9)</td><td>20 (27.8)</td><td>5 (55.6)</td><td>0.126</td></tr><tr><td>History of diabetes mellitus</td><td>19 (23.2)</td><td>18 (24.7)</td><td>1 (11.1)</td><td>0.677</td></tr><tr><td>History of hypertension</td><td>52 (63.4)</td><td>46 (63.0)</td><td>6 (66.7)</td><td>1.000</td></tr><tr><td>History of cardiomyopathy</td><td>44 (53.7)</td><td>39 (53.4)</td><td>5 (55.6)</td><td>1.000</td></tr><tr><td>History of myocardial infarction</td><td>16 (19.5)</td><td>13 (17.8)</td><td>3 (33.3)</td><td>0.368</td></tr><tr><td>History of congestive heart failure</td><td>26 (31.7)</td><td>23 (31.5)</td><td>3 (33.3)</td><td>1.000</td></tr><tr><td>History of stroke and/or transient ischemic attack</td><td>16 (19.5)</td><td>14 (19.2)</td><td>2 (22.2)</td><td>1.000</td></tr><tr><td>CHA2DS2-VASc score, med (IQR)</td><td>4 (3–5)</td><td>4 (3–5)</td><td>5 (3–5)</td><td>0.957</td></tr><tr><td>HAS-BLED score, med (IQR)</td><td>2 (2–3)</td><td>2 (2–3)</td><td>3 (2–4)</td><td>0.111</td></tr><tr><td>Regular use of vitamin K antagonist prior to COVID-19</td><td>9 (11.0)</td><td>6 (8.2)</td><td>3 (33.3)</td><td>0.056</td></tr><tr><td><strong>Hospitalization data</strong></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-sinus heart rhythm on admission</td><td>30 (36.6)</td><td>28 (38.4)</td><td>2 (22.2)</td><td>0.475</td></tr><tr><td>Use of antibiotics ‡</td><td>59 (72.0)</td><td>52 (71.2)</td><td>7 (77.8)</td><td>1.000</td></tr><tr><td>Use of pharmacological treatments of respiratory disorders <sup>11</sup></td><td>9 (11.0)</td><td>6 (8.2)</td><td>3 (33.3)</td><td>0.056</td></tr><tr><td>Estimated glomerular filtration rate (mL/min) §, med (IQR)</td><td>71.6 (52.8–93.1)</td><td>71.8 (53.7–92.7)</td><td>42.6 (34.2–101.4)</td><td>0.244</td></tr></tbody></table>

Data presented as *n* (%) where applicable; CHA2DS2-VASc score for atrial fibrillation stroke risk; GIR: iso resource groups; HAS-BLED score for major bleeding risk; IQR: interquartile range; * between-group comparisons based on Fisher's exact test or Mann-Whitney Wilcoxon test, as appropriate; † serum albumin concentration < 30 g/L; ‡ quinolones, beta-lactams, sulfonamides, macrolides, lincosamides, aminoglycosides, among others; <sup>11</sup> beta2-adrenergic agonists, inhaled corticosteroids, antihistamines, among others; § estimated using the modification of diet in renal disease (MDRD) study equation.

After appropriately adjusting for the propensity score, the weighted Cox model found a direct association between the regular use of VKA prior to COVID-19 and the 7-day mortality. While considering "using no VKA" as the reference (HR = 1), the HR for mortality in those using VKA on a regular basis was 5.68 [95% CI: 1.17; 27.53] (*p* = 0.0312).

The sensitivity analysis using the unadjusted, partially adjusted and fully adjusted Cox models confirmed the results of the propensity score approach (Table S1).
Le document avec l'identifiant n'est pas visible actuellement !

Retourner à l'accueil

[image]

[image]

[image]

[image]

Contact

• Support

Ressources

• Documentation

• FAQ

• API

• OAI-PMH

• AuréHAL

Informations

• À propos

• Données personnelles

• Mentions légales

• Accessibilité

• Conformité RGAA

Questions juridiques

• Je publie, quels sont mes droits ?

• Loi pour une République numérique

• Stratégie de non-cession des droits

• SHERPA/RoMEO

Portails

• Portails institutionnels

• HAL

• HAL SHS

• HAL Thèses
Consistently, Kaplan–Meier distributions, drawn without propensity score adjustment in Figure 1, showed that COVID-19 patients using VKA on a regular basis had shorter survival times than those not using VKA.

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Kaplan–Meier estimates of the cumulative probability of COVID-19 participants’ survival according to the regular use of vitamin K antagonist (VKA) prior to COVID-19 (n = 82).</figcaption></figure>

**4. Discussion**

The main result of this cohort study is that, irrespective of all measured covariables, the regular use of VKA prior to COVID-19 was associated with a lower survival rate in hospitalized frail elderly patients with COVID-19. This novel finding calls for the careful use of VKA in this population and to prefer anticoagulants that do not disrupt the vitamin K cycle when there is an indication for anticoagulation. This lesson for routine practice is consistent with current guidelines encouraging to use of DOACs first-line after age 75 [11].

To our knowledge, we provide here the first data examining the association of the regular use of VKA prior to COVID-19 with the survival rate of COVID-19 patients. One previous cohort study has examined the association of the use of anticoagulants (i.e., VKAs, DOACs or heparins) prior to (and during the earliest stages of) COVID-19 with the outcomes of COVID-19 [14]. The authors found from 3772 patients (n = 241 using anticoagulants, without further clarification on the use of VKA specifically) that the anticoagulation brought no benefit in preventing severe forms of COVID-19 and in reducing all-cause mortality [14]. Moreover, taking into account the ongoing uncertainty regarding the role of a procoagulant state in the pathophysiology of severe COVID-19, some have opted to use anticoagulants as a treatment option for patients with already diagnosed COVID-19. For instance, prophylactic heparin was used in 99 patients with COVID-19 in Wuhan, China, and was associated with improved survival in the specific subgroup with a sepsis-induced coagulopathy score ≥ 4 [15]. However, the rate of prophylactic anticoagulation was rather low for some poorly defined reason [15]. In addition, the use of anticoagulants of all classes
• MédiHAL

CCSD

• CCSD

• Episciences

• Sciencesconf
was associated in 4389 patients hospitalized for COVID-19 in 5 New York hospitals, with reduced mortality and reduced use of intubation [16]. However, a significant proportion of patients had taken more than one anticoagulant during hospitalization in this study, which precluded a direct comparison between anticoagulants and prevented from determining the selective effect of VKAs. Moreover, the absence of randomization in this observational study precluded the inference that anticoagulation provided a benefit in the observed reduction in mortality and intubation. The reasons why the patients were not treated with anticoagulants may be related to their underlying frailty or to the concomitant presence of severe bleeding history, thrombocytopenia or coagulopathy, all of which may alter patient prognosis. The benefit of anticoagulation in reducing thrombotic complications should, therefore, be weighed against the risks of adverse effects such as major bleeding, but also the reduction of vitamin K concentrations when taking VKA. Thus, our present results provide novel information by reporting that the long-term use of VKA prior to COVID-19 was specifically associated with increased mortality risk in COVID-19 patients, which should be taken into account in clinical decisions and in the choice of anticoagulant.

How vitamin K status is associated with COVID-19 survival is not fully elucidated. Four mechanisms are likely: regulation of (i) anticoagulation, (ii) lung fibrosis, (iii) inflam-
mation, and (iv) host frailty and comorbidities. First, coagulation is a complex balance
between the processes of promoting and dissolving clots. The carboxylation and biological
function of coagulation factors II, VII, IX and X depend on vitamin K. A decrease in vitamin
K leads to more severely compromised carboxylation of extrahepatic proteins than of
vitamin K-dependent hepatic proteins [17], which may paradoxically lead to thrombo-
genicity [18]. Second, vitamin K is involved, via the matrix Gla protein (MGP) [19], in the
regulation of calcifications in the arterial walls and in the lung matrix [20,21]. Since MGP
needs vitamin K to become biologically active, the under-carboxylation of MGP due to 6
weeks of treatment with VKA was associated with accelerated arterial calcification [22]. It
is also suspected that the compromise of the MGP carboxylation by VKA is involved in
the onset of idiopathic pulmonary fibrosis [23,24] since elastic fibers have a strong affinity
with calcium [25]. Of note, uncarboxylated MGP has been shown to worsen outcomes
mainly in atherosclerotic, diabetic and hemodialysis patients, in whom supplementary
vitamin K2 treatment may reduce inactive MGP levels [26]. Lung fibrosis may also be exac-
erbated with VKA by preventing the activation of anticoagulant proteins C and S, which
both have antifibrotic properties [27,28]. Third, vitamin K exerts an anti-inflammatory
effect mediated by the reduction of PGE2, COX2 and IL-6 [29]. Vitamin K deficiency due
to the use of VKA is accompanied by an increase in circulating levels of inflammatory
cytokines such as IL-6 and C-reactive protein [29]. Similarly, one recent study reported that
vitamin K deficiency in male COVID-19 patients was associated with greater IL-6 levels
in the general circulation [30]. This suggests that vitamin K deficiency may be involved
in the COVID-19 cytokine storm and related fatal outcomes, including ARDS [1]. Fourth,
reduced vitamin K status is associated with comorbidities such as hypertension, diabetes
mellitus and cardiovascular disease [1,6,30], which are known to contribute to the severity
of COVID-19 [1].

We also noted here that female sex was associated with lower 7-day mortality (Table S1). This result is consistent with previous literature that points out a special vulnerability of men to COVID-19 [1]. Thus, this result validates the consistency of our cohort and of our main result, i.e., the association of the regular use of VKA with poorer survival in COVID-19 patients.

The strengths of the present study include (i) the originality of the research question on an emerging infection for which there is no scientifically validated treatment and in which every effort should be made to improve the prognosis, (ii) the follow-up and the detailed description of the participants' characteristics allowing the use of a propensity-score-weighted Cox proportional-hazards model to measure adjusted longitudinal associations according to regular use of VKA prior to COVID-19, and (iii) the standardized collection of data from a single research center. Regardless, a number of limitations also existed.
First, the study participants were restricted to a limited number of hospitalized frail elderly patients, with a relatively low proportion under VKA, who may be unrepresentative of all older adults. Second, although we were able to control for important characteristics that could modify the association, residual potential confounders may still be present such as the serum phylloquinone concentration (which is commonly low in older adults [30]), the dietary vitamin K intake, or the history of INR prior to and during COVID-19. Third, the observational design of our study is less robust than an interventional study and prevents any causal inference, even if using a propensity score, defined as the probability of treatment assignment conditional on baseline covariables, is helpful for estimating the effects of treatments from observational data in an unbiased way [12].

**5. Conclusions**

We were able to report among hospitalized frail elderly patients with COVID-19 an increased mortality risk at day 7 associated with the regular use of VKA prior to COVID-19. Even if the benefits of anticoagulation are indisputable for indications such as atrial fibrillation [11], further larger prospective observational cohorts and randomized clinical trials, preferentially on a variety of adult populations, are needed to clarify the prognosis of COVID-19 among those using VKA on a regular basis compared to those using DOAC, and whether there is a differential effect on the prognosis according to the time of anticoagulant administration prior to or following the diagnosis of COVID-19. Determining whether vitamin K supplementation has an interest in the prevention and treatment of severe COVID-19 will also be important.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/2072-6643/13/1/39/s1, Table S1: Univariate and multiple Cox proportional-hazards model showing the hazard ratio for 7-day mortality (dependent variable) according to the regular use of vitamin K antagonist prior to COVID-19 (independent variable), adjusted for participants' characteristics (n = 82).

**Author Contributions:** C.A. has full access to all of the data in the study, takes responsibility for the data, the analyses and interpretation and has the right to publish any and all data, separate and apart from the attitudes of the sponsors. All authors have read and approved the manuscript. Study concept and design: C.A. Acquisition of data: P.M., O.B., G.S., A.B. and C.A. Analysis and interpretation of data: P.M., J.G., J.R., A.B. and C.A. Drafting of the manuscript: P.M. and C.A. Critical revision of the manuscript for important intellectual content: O.B., J.G., J.R., G.S. and A.B. Obtained funding: Not applicable. Statistical expertise: J.G. and J.R. Administrative, technical, or material support: C.A. Study supervision: C.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** G.S. is supported by a postdoctoral grant from the Research Center on Autonomy and Longevity, University Hospital of Angers, France (2019–2020). The sponsors had no role in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the University Hospital of Angers, France (2020/100).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Patient level data are freely available from the last author at Cedric.Annweiler@chu-angers.fr. There is no personal identification risk within this anonymized raw data, which is available after notification and authorization of the competent authorities.

**Acknowledgments:** The authors wish to thank the GERIA-COVID study group. GERIA-COVID study group: Cédric Annweiler, Marine Asfar, Mélinda Beaudenon, Jean Barré, Antoine Brangier, Mathieu Corvaisier, Guillaume Duval, Jennifer Gautier, Mialy Guenet, Jocelyne Loison, Frédéric Noublanche, Marie Otekpo, Hélène Rivière, Guillaume Sacco, Romain Simon. Affiliation: Department of Geriatric Medicine, University Hospital, Angers, France. The authors have listed everyone who con-
tributed significantly to the work in the Acknowledgments section. Permission was obtained from all
persons named in the Acknowledgments section. There was no compensation for this contribution.

**Conflicts of Interest:** C.A. serves as an editorial board member for *Nutrients* and occasionally serves as a consultant for *Bayer France*. All authors declare they do not have any other financial and personal conflicts of interest with this manuscript.

References

1. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* **2020**, *395*, 1054–1062.
[CrossRef]

2. Cui, S.; Chen, S.; Li, X.; Liu, S.; Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 1421–1424. [CrossRef]

3. Tang, N.; Li, D.; Wang, X.; Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J. Thromb. Haemost.* **2020**, *18*, 844–847. [CrossRef]

4. Dofferhoff, A.S.M.; Piscaer, I.; Schurgers, L.J.; Visser, M.P.J.; Ouweland, J.M.W.V.D.; A De Jong, P.; Gosens, R.; Hackeng, T.M.; Van Daal, H.; Lux, P.; et al. Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19. *Clin. Infect. Dis.* **2020**. [CrossRef]

5. Luo, W.-R.; Yu, H.; Gou, J.-Z.; Li, X.-X.; Sun, Y.; Li, J.-X.; He, J.-X.; Liu, L. Histopathological Findings in the Explant Lungs of a Patient With COVID-19 Treated With Bilateral Orthotopic Lung Transplant. *Transplantation* **2020**, *104*, e329–e331. [CrossRef]

6. Fraser, J.D.; A Price, P. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. *Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J. Biol. Chem.* **1988**, *263*, 11033–11036.

7. Ansell, J.; Hirsh, J.; Hylek, E.; Jacobson, A. Crowther M, Palareti G. American College of Chest Physicians: Pharmacology and Management of the Vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* **2008**, *133*, 160S–198S. [CrossRef]

8. French National Security Agency of Medicines and Health Products (ANSM). Anticoagulants in France in 2012: Inventory and Monitoring. Available online: http://ansm.sante.fr/var/ansm_site/storage/original/application/901e9c291a545dff52c0b41365c0d6e2.pdf (accessed on 26 November 2020).

9. Gasecka, A.; Borovac, J.A.; Guerreiro, R.A.; Giustozzi, M.; Parker, W.A.; Caldeira, D.; Chiva-Blanch, G. Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment. *Cardiovasc. Drugs Ther.* **2020**, *20*, 1–15. [CrossRef]

10. Vetel, J.M.; Leroux, R.; Ducoudray, J.M. AGGIR. Practical use. Geriatric Autonomy Group Resources Needs. *Soins Gérontol.* **1998**, *13*, 23–27.

11. Developed with the special contribution of the European Heart Rhythm Association (EHRA); Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; Van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). *Eur. Heart J.* **2010**, *31*, 2369–2429. [CrossRef]

12. Li, F.; Morgan, K.L.; Zaslavsky, A.M. Balancing Covariates via Propensity Score Weighting. *J. Am. Stat. Assoc.* **2018**, *113*, 390–400. [CrossRef]

13. Flaczyk, A.; Rosovsky, R.; Reed, C.T.; Bankhead-Kendall, B.K.; Bittner, E.A.; Chang, M.G. Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: Implications for clinical practice and future investigations. *Crit. Care* **2020**, *24*, 1–13. [CrossRef] [PubMed]

14. Tremblay, D.; Van Gerwen, M.; Alsen, M.; Thibaud, S.; Kessler, A.; Venugopal, S.; Makki, I.; Qin, Q.; Dharmapuri, S.; Jun, T.; et al. Impact of anticoagulation prior to COVID-19 infection: A propensity score–matched cohort study. *Blood* **2020**, *136*, 144–147. [CrossRef] [PubMed]

15. Tang, N.; Bai, H.; Chen, X.; Gong, J.; Li, D.; Sun, Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J. Thromb. Haemost.* **2020**, *18*, 1094–1099. [CrossRef]

16. Nadkarni, G.N.; Lala, A.; Bagiella, E.; Chang, H.L.; Moreno, P.R.; Pujadas, E.; Arvind, V.; Bose, S.; Charney, A.W.; Chen, M.D. et al. Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. *J. Am. Coll. Cardiol.* **2020**, *76*, 1815–1826. [CrossRef]

17. Booth, S.L.; Martini, L.; Peterson, J.W.; Saltzman, E.; Dallal, G.E.; Wood, R.J. Dietary Phylloquinone Depletion and Repletion in Older Women. *J. Nutr.* **2003**, *133*, 2565–2569. [CrossRef]

18. Nigwekar, S.U.; Thadhani, R.; Brandenburg, V.M. Calciphylaxis. *N. Engl. J. Med.* **2018**, *378*, 1704–1714. [CrossRef]

19. Chatrou, M.L.; Winckers, K.; Hackeng, T.M.; Reutelingsperger, C.P.; Schurgers, L.J. Vascular calcification: The price to pay for anti-coagulation therapy with vitamin K-antagonists. *Blood Rev.* **2012**, *26*, 155–166. [CrossRef]

20. Price, P.A.; Buckley, J.R.; Williamson, M.K. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vita-min D-induced calcification of arteries, cartilage, lungs and kidneys in rats. *J. Nutr.* **2001**, *131*, 2910–2915. [CrossRef]

21. Rucker, R.B. Calcium Binding to Elastin. *Adv. Exp. Med. Biol.* **1974**, *48*, 185–209. [CrossRef]
22. Schurgers, L.J.; Spronk, H.M.; Soute, B.A.; Schiffers, P.M.; DeMey, J.G.; Vermeer, C. Regression of warfarin-induced medial elastocal-cinosis by high intake of vitamin K in rats. *Blood* **2007**, *109*, 2823-2831. [CrossRef]

23. Hardie, W.D.; Korfhagen, T.R.; Sartor, M.A.; Prestridge, A.; Medvedovic, M.; Le Cras, T.D.; Ikegami, M.; Wesselkamper, S.C.; Davidson, C.; Dietsch, M.; et al. Genomic profile of matrix and vasculature remodeling in TGF-α in-duced pulmonary fibrosis. *Am. J. Respir. Cell. Mol. Biol. 2007*, *37*, 309-321. [CrossRef] [PubMed]

24. Booth, A.J.; Hadley, R.; Cornett, A.M.; Dreffs, A.A.; Matthes, S.A.; Tsui, J.L.; Weiss, K.; Horowitz, J.C.; Fiore, V.F.; Barker, T.H.; et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. *Am. J. Respir. Crit. Care Med.* **2012**, *186*, 866-876. [CrossRef]

25. Basalyga, D.M.; Simionescu, D.T.; Xiong, W.; Baxter, B.T.; Starcher, B.C.; Vyavahare, N.R. Elastin degradation and calcification in an abdominal aorta injury model: Role of matrix metalloproteinases. *Circulation* **2004**, *110*, 3480-3487. [CrossRef]

26. Westenfeld, R.; Krueger, T.; Schlieper, G.; Cranenburg, E.C.; Magdeleyns, E.J.; Heidenreich, S. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: A randomized trial. *Am. J. Kidney Dis.* **2012**, *59*, 186-195. [CrossRef] [PubMed]

27. Urawa, M.; Kobayashi, T.; D'Alessandro-Gabazza, C.N.; Fujimoto, H.; Toda, M.; Roeffen, Z.; A Hinneh, J.; Yasuma, T.; Takei, Y.; Taguchi, O.; et al. Protein S is protective in pulmonary fibrosis. *J. Thromb. Haemost.* **2016**, *14*, 1588-1599. [CrossRef]

28. Lin, C.; Von Der Thüsen, J.; Isermann, B.; Weiler, H.; Van Der Poll, T.; Borensztajn, K.; Spek, C.A. High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis. *J. Cell. Mol. Med.* **2016**, *20*, 2029-2035. [CrossRef]

29. Suleiman, L.; Negrier, C.; Boukerche, H. Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the cross-roads of coagulation, inflammation, angiogenesis, and cancer. *Crit. Rev. Oncol. Hematol.* **2013**, *88*, 637-654. [CrossRef]

30. Anastasi, E.; Ialongo, C.; Labriola, R.; Ferraguti, G.; Lucarelli, M.; Angeloni, A. Vitamin K deficiency and covid-19. *Scand. J. Clin. Lab. Investig.* **2020**, *80*, 525-527. [CrossRef] [PubMed]